Wellness Research Center Inc — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$1,147,334	388
2024	Research	$1,074,844	271
2023	Research	$628,225	10
2022	Research	$539,660	13
2021	Research	$5,000	1

Breakdown

Who paid Research payments · program years 2021–2025

ITI, Inc. $1,818,558 611 payments
Genentech, Inc. $856,714 16 payments
Janssen Research & Development, LLC $662,092 21 payments
Sumitomo Pharma America, Inc. $52,199 33 payments
Purdue Pharma L.P. $5,500 2 payments

Studies the money was for Research payments · program years 2021–2025

Iti-007-452 $1,635,706 528 payments
Roche Cancer Screening Collection Study $856,714 16 payments
A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older $549,435 14 payments
Iti-1284-101 $131,096 56 payments
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) $112,657 7 payments
Iti-1284-201 $51,756 27 payments
A 24-Week, Open-Label Study Evaluating the Effectiveness, Safety and Tolerability of Sep-363856 in Subjects With Schizophrenia Switched From Typical Or Atypical Antipsychotic Agents Ole. $19,803 8 payments
An 8-Week, Open-Label Study Evaluating the Effectiveness, Safety and Tolerability of Sep-363856 in Subjects With Schizophrenia Switched From Typical Or Atypical Antipsychotic Agents $17,808 7 payments
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication $14,588 18 payments
Real-world Evidence of Duration of Adhansia XR for treatment of ADHD (REDAX): An open-label pragmatic study to assess the real-world effectiveness of Adhansia XR in treatment of adult and adolescent patients with ADHD in the United States $5,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.